Recro Pharma Reports Positive Top-Line Results from Pivotal Phase III Clinical Trial of IV Meloxicam, Achieves Primary Endpoint And 10 Secondary Endpoints; Estimates USNDA Filing Summer 2017
Paul Quintaro